Superficial bladder cancer does recur despite bacillus Calmette–Guérin (BCG) instillations—currently the most effective prophylactic therapy. Antifibrinolytic agents seem to enhance the efficacy of ...

Patients who received intravesical BCG instillation following surgery for nonmuscle-invasive bladder cancer had a lower risk of recurrence of upper tract urothelial carcinoma and bladder cancer, a ...

Protara Therapeutics (NASDAQ:TARA) shared updated interim data from its ongoing Phase 2, open-label ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle invasive ...

Radium-223 and atezolizumab in platinum refractory urothelial carcinoma with bone metastases: NCT03208712. Background: BCG unresponsive NMIBC includes patients with persistent high-grade disease or ...

A 65-year-old man with a history of T1 high-grade bladder cancer with CIS underwent successful transurethral resection of bladder tumor (TURBT), without residual tumor on second resection. Given his ...

BCG therapy for NMIBC is associated with significant symptoms and side effects, but combining it with chemotherapy reduces these effects. BCG induction with maintenance is less toxic than induction ...

The association between allopurinol use and urologic malignancies: A nested case-control study. This is an ASCO Meeting Abstract from the 2020 Genitourinary Cancers Symposium. This abstract does not ...

Imfinzi addition to BCG therapy significantly improved DFS in high-risk NMIBC patients, with a 32% reduction in DFS events. The study involved 1,018 patients, with three cohorts receiving different ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s largest independent providers of ...

WASHINGTON -- The gene therapy nadofaragene firadenovec (Adstiladrin) continued to demonstrate clinical activity in patients with high-risk bladder cancer, researchers reported. The long-term ...